Read More Pharma Industry News Eli Lilly (NYSE: LLY) to acquire AtaiBeckley in $3.8bn TRD psychedelic deal Eli Lilly (NYSE: LLY) to acquire AtaiBeckley for $6.75/share cash plus $2.50 CVR, taking the BPL-003 5-MeO-DMT depression asset to Phase 3 read in 2029. byVenkateshJuly 16, 2026